Only 2% of the ALL cases resulted CD22-negative (0–0.2% of positive blasts), 2% showed CD22 positivity in 1–10% of the blasts, 14% in 11–50% of the blasts, 16% in 51–90% of the blasts, and 55% in >90% of the blasts. Here, CD22 is linked to acute lymphoblastic leukemia.